SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis
NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD
Overall SUPN gets a fundamental rating of 7 out of 10. We evaluated SUPN against 198 industry peers in the Pharmaceuticals industry. SUPN gets an excellent profitability rating and is at the same time showing great financial health properties. A decent growth rate in combination with a cheap valuation! Better keep an eye on SUPN. This makes SUPN very considerable for value and quality investing!
1. Profitability
1.1 Basic Checks
In the past year SUPN was profitable.
SUPN had a positive operating cash flow in the past year.
In the past 5 years SUPN has always been profitable.
Each year in the past 5 years SUPN had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 5.40%, SUPN belongs to the best of the industry, outperforming 90.40% of the companies in the same industry.
SUPN's Return On Equity of 7.13% is amongst the best of the industry. SUPN outperforms 86.87% of its industry peers.
The Return On Invested Capital of SUPN (5.18%) is better than 82.32% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 41.77%.
The last Return On Invested Capital (5.18%) for SUPN is above the 3 year average (2.70%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 7.13% | ||
| ROIC | 5.18% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
SUPN's Profit Margin of 11.16% is amongst the best of the industry. SUPN outperforms 87.88% of its industry peers.
In the last couple of years the Profit Margin of SUPN has declined.
SUPN has a better Operating Margin (13.68%) than 83.33% of its industry peers.
In the last couple of years the Operating Margin of SUPN has declined.
SUPN's Gross Margin of 89.57% is amongst the best of the industry. SUPN outperforms 90.40% of its industry peers.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.68% | ||
| PM (TTM) | 11.16% | ||
| GM | 89.57% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SUPN has been increased compared to 5 years ago.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SUPN has an Altman-Z score of 4.67. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.67, SUPN belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.67 |
ROIC/WACC0.54
WACC9.57%
2.3 Liquidity
A Current Ratio of 2.35 indicates that SUPN has no problem at all paying its short term obligations.
SUPN's Current ratio of 2.35 is in line compared to the rest of the industry. SUPN outperforms 44.44% of its industry peers.
A Quick Ratio of 2.16 indicates that SUPN has no problem at all paying its short term obligations.
With a Quick ratio value of 2.16, SUPN perfoms like the industry average, outperforming 47.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 2.16 |
3. Growth
3.1 Past
SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.43%, which is quite impressive.
SUPN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.78% yearly.
Looking at the last year, SUPN shows a quite strong growth in Revenue. The Revenue has grown by 8.92% in the last year.
Measured over the past years, SUPN shows a quite strong growth in Revenue. The Revenue has been growing by 11.00% on average per year.
EPS 1Y (TTM)81.43%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%-15.73%
Revenue 1Y (TTM)8.92%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%5.99%
3.2 Future
The Earnings Per Share is expected to grow by 15.19% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.24% on average over the next years.
EPS Next Y-21.16%
EPS Next 2Y1%
EPS Next 3Y8.78%
EPS Next 5Y15.19%
Revenue Next Year-2.99%
Revenue Next 2Y2.98%
Revenue Next 3Y5.66%
Revenue Next 5Y7.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.06, SUPN is valued correctly.
Compared to the rest of the industry, the Price/Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 88.38% of the companies listed in the same industry.
SUPN's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.63.
SUPN is valuated correctly with a Price/Forward Earnings ratio of 15.29.
Based on the Price/Forward Earnings ratio, SUPN is valued cheaper than 83.33% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.85, SUPN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.06 | ||
| Fwd PE | 15.29 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SUPN is valued cheaper than 95.45% of the companies in the same industry.
SUPN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SUPN is cheaper than 90.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.97 | ||
| EV/EBITDA | 4.97 |
4.3 Compensation for Growth
SUPN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.19
EPS Next 2Y1%
EPS Next 3Y8.78%
5. Dividend
5.1 Amount
SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SUPN (4/22/2025, 2:29:54 PM)
30.6198
+0.33 (+1.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners112.49%
Inst Owner Change0.13%
Ins Owners3.99%
Ins Owner Change2.67%
Market Cap1.71B
Analysts78.18
Price Target39.58 (29.26%)
Short Float %11.5%
Short Ratio10.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100.07%
Min EPS beat(2)41.4%
Max EPS beat(2)158.74%
EPS beat(4)2
Avg EPS beat(4)39.58%
Min EPS beat(4)-32.33%
Max EPS beat(4)158.74%
EPS beat(8)5
Avg EPS beat(8)43.4%
EPS beat(12)6
Avg EPS beat(12)20.04%
EPS beat(16)8
Avg EPS beat(16)17.72%
Revenue beat(2)2
Avg Revenue beat(2)9.74%
Min Revenue beat(2)9.5%
Max Revenue beat(2)9.98%
Revenue beat(4)3
Avg Revenue beat(4)6.73%
Min Revenue beat(4)-3.43%
Max Revenue beat(4)10.86%
Revenue beat(8)6
Avg Revenue beat(8)4.62%
Revenue beat(12)8
Avg Revenue beat(12)2.47%
Revenue beat(16)11
Avg Revenue beat(16)2.27%
PT rev (1m)0%
PT rev (3m)-1.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.47%
EPS NY rev (1m)1.9%
EPS NY rev (3m)3.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.44%
Revenue NY rev (1m)-0.74%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.06 | ||
| Fwd PE | 15.29 | ||
| P/S | 2.58 | ||
| P/FCF | 9.97 | ||
| P/OCF | 9.93 | ||
| P/B | 1.65 | ||
| P/tB | 4.3 | ||
| EV/EBITDA | 4.97 |
EPS(TTM)2.54
EY8.3%
EPS(NY)2
Fwd EY6.54%
FCF(TTM)3.07
FCFY10.03%
OCF(TTM)3.08
OCFY10.07%
SpS11.87
BVpS18.58
TBVpS7.12
PEG (NY)N/A
PEG (5Y)3.19
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 7.13% | ||
| ROCE | 8.42% | ||
| ROIC | 5.18% | ||
| ROICexc | 8.95% | ||
| ROICexgc | N/A | ||
| OM | 13.68% | ||
| PM (TTM) | 11.16% | ||
| GM | 89.57% | ||
| FCFM | 25.87% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.9% | ||
| Cap/Sales | 0.11% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.57% | ||
| Profit Quality | 231.81% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 2.16 | ||
| Altman-Z | 4.67 |
F-Score8
WACC9.57%
ROIC/WACC0.54
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)81.43%
EPS 3Y37.36%
EPS 5Y3.78%
EPS Q2Q%-15.73%
EPS Next Y-21.16%
EPS Next 2Y1%
EPS Next 3Y8.78%
EPS Next 5Y15.19%
Revenue 1Y (TTM)8.92%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%5.99%
Revenue Next Year-2.99%
Revenue Next 2Y2.98%
Revenue Next 3Y5.66%
Revenue Next 5Y7.24%
EBIT growth 1Y508.11%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year87.07%
EBIT Next 3Y-4.36%
EBIT Next 5Y21.99%
FCF growth 1Y54.91%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y54.79%
OCF growth 3Y10.6%
OCF growth 5Y3.74%